Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about DBVT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
DBVT holds $165.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $52.1M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
There have been no material changes in our risk factors from those disclosed in the Annual Report except as follows: There is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.10-Q, Oct 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DBVT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 25,586,190 | 8.14% | 2026-01-12 |
| Raymond Debbane | 5%+ holder (13G) | 24,716,176 | 7.86% | 2026-09-30 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 22,272,884 | 7.08% | 2026-03-31 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 20,469,392 | 6.51% | 2025-12-31 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 18,288,220 | 5.82% | 2026-07-30 |
| Bpifrance SA 10% owner |
Insider | 10,898,595 | 3.47% | 2025-03-27 |
| Bpifrance EPIC Member of 10% owner group |
Insider | 7,529,502 | 2.39% | 2025-12-17 |
| Investissement S.A.S. Bpifrance Member of 10% owner group |
Insider | 226,133 | 0.07% | 2025-03-27 |
| Pharis Mohideen Chief Medical Officer · +683,000 options |
Insider | 144,531 | 0.05% | 2026-07-29 |
| Virginie Boucinha Chief Financial Officer · +418,000 options |
Insider | 70,000 | 0.02% | 2025-11-21 |
| Kevin Michael Trapp Chief Commercial Officer · +316,250 options |
Insider | 55,000 | 0.02% | 2025-11-21 |
| Daniel Tasse CHIEF EXECUTIVE OFFICER, Director · +2.58M options |
Insider | 17,094 | 0.01% | 2024-03-08 |
Share count 314,388,807 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DBVT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →